Eagle Pharmaceutical (EGRX) 60.34 $EGRX Chemical

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 11:24 PM

Eagle Pharmaceutical (EGRX) 60.34 $EGRX

Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Mon Aug 22, 4:51PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
SPGI: 125.43 (+1.49), TLMR: 23.26 (-0.44), SVU: 5.72 (+0.21), SCVL: 26.17 (-0.01), FCFS: 52.83 (+2.51), SGNT: 21.76 (+0.03), EGRX: 60.34 (+1.32), CHFC: 44.36 (-0.65), CSH: 42.20 (-1.33)

InvestorsObserver releases covered-call reports for Netflix, Nevro Corporation, Eagle Pharmaceuticals, Mylan and Weibo
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EGRX, MYL, NFLX, NVRO, and WB.
NFLX: 97.38 (unch), WB: 49.54 (+0.52), MYL: 39.97 (-1.95), EGRX: 60.34 (+1.32), NVRO: 95.91 (-0.11)

Eagle Pharmaceuticals (EGRX) Soars: Stock Moves 14.6% Higher
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:00AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise over 14% on the day
LNTH: 9.40 (-0.10), EGRX: 60.34 (+1.32)

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
BusinessWire - Tue Aug 09, 5:50AM CDT
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"

(Nasdaq:EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:
EGRX: 60.34 (+1.32)

Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
BusinessWire - Tue Aug 09, 5:45AM CDT
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
EGRX: 60.34 (+1.32)

Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 12.52 (+0.05), STE: 71.00 (+0.89), EGRX: 60.34 (+1.32), PEN: 70.63 (+0.61), OMER: 11.10 (+0.34)

SHAREHOLDER ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important August 1 Deadline in Class Action - EGRX
GlobeNewswire - Mon Aug 01, 6:00PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period"

of the important August 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 60.34 (+1.32)

EGRX Investors: The Wagner Firm Announces The Filing Of A Securities Class Action On Behalf of Eagle Pharmaceuticals Inc. Investors
BusinessWire - Mon Aug 01, 12:40PM CDT
The Wagner Firm announces the filing of a class action lawsuit on behalf of investors who purchased Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the "Class Period"

. Eagle investors have until August 1, 2016 to file a lead plaintiff motion.
EGRX: 60.34 (+1.32)

3-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jul 29, 10:59AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 29, 2016 / Lundin Law PC (the "Firm"

announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(NASDAQ: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the "Class Period"

. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
EGRX: 60.34 (+1.32)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 29, 8:27AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period"

, are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline.
EGRX: 60.34 (+1.32)

INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws.
EGRX: 60.34 (+1.32)

EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 60.34 (+1.32)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)

Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.74 (+0.06), HCP: 39.08 (+0.28), UNIS: 2.79 (+0.01), CBL: 13.65 (+0.05), INFI: 1.56 (+0.04), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)

Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 36.98 (-0.02), CBL: 13.65 (+0.05), TRXC: 1.39 (+0.02), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
EGRX: 60.34 (+1.32)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...